146 related articles for article (PubMed ID: 33724593)
1. Cucurbitacin IIa: A review of phytochemistry and pharmacology.
Zeng Y; Wang J; Huang Q; Ren Y; Li T; Zhang X; Yao R; Sun J
Phytother Res; 2021 Aug; 35(8):4155-4170. PubMed ID: 33724593
[TBL] [Abstract][Full Text] [Related]
2. Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation.
Boykin C; Zhang G; Chen YH; Zhang RW; Fan XE; Yang WM; Lu Q
Br J Cancer; 2011 Mar; 104(5):781-9. PubMed ID: 21304528
[TBL] [Abstract][Full Text] [Related]
3. Potential of cucurbitacin as an anticancer drug.
Li Y; Li Y; Yao Y; Li H; Gao C; Sun C; Zhuang J
Biomed Pharmacother; 2023 Dec; 168():115707. PubMed ID: 37862969
[TBL] [Abstract][Full Text] [Related]
4. Cucurbitacins: A Systematic Review of the Phytochemistry and Anticancer Activity.
Cai Y; Fang X; He C; Li P; Xiao F; Wang Y; Chen M
Am J Chin Med; 2015; 43(7):1331-50. PubMed ID: 26503558
[TBL] [Abstract][Full Text] [Related]
5. Apoptotic and antimetastatic effect of cucurbitacins in cancer: recent trends and advancement.
Kumar A; Sharma B; Sharma U; Parashar G; Parashar NC; Rani I; Ramniwas S; Kaur S; Haque S; Tuli HS
Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep; 396(9):1867-1878. PubMed ID: 37010571
[TBL] [Abstract][Full Text] [Related]
6. Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics.
Dai S; Wang C; Zhao X; Ma C; Fu K; Liu Y; Peng C; Li Y
Pharmacol Res; 2023 Jan; 187():106587. PubMed ID: 36460279
[TBL] [Abstract][Full Text] [Related]
7. Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.
Premkumar DR; Jane EP; Pollack IF
Cancer Biol Ther; 2015; 16(2):233-43. PubMed ID: 25482928
[TBL] [Abstract][Full Text] [Related]
8. STAT3-independent inhibition of lysophosphatidic acid-mediated upregulation of connective tissue growth factor (CTGF) by cucurbitacin I.
Graness A; Poli V; Goppelt-Struebe M
Biochem Pharmacol; 2006 Jun; 72(1):32-41. PubMed ID: 16707113
[TBL] [Abstract][Full Text] [Related]
9. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity.
Sun J; Blaskovich MA; Jove R; Livingston SK; Coppola D; Sebti SM
Oncogene; 2005 May; 24(20):3236-45. PubMed ID: 15735720
[TBL] [Abstract][Full Text] [Related]
10. Cucurbitacins and the Immune System: Update in Research on Anti- inflammatory, Antioxidant, and Immunomodulatory Mechanisms.
Silvestre GFG; de Lucena RP; da Silva Alves H
Curr Med Chem; 2022; 29(21):3774-3789. PubMed ID: 34994307
[TBL] [Abstract][Full Text] [Related]
11. Cucurbitacin-I, a natural cell-permeable triterpenoid isolated from Cucurbitaceae, exerts potent anticancer effect in colon cancer.
Kim HJ; Park JH; Kim JK
Chem Biol Interact; 2014 Aug; 219():1-8. PubMed ID: 24858077
[TBL] [Abstract][Full Text] [Related]
12. Cucurbitacin IIa induces caspase-3-dependent apoptosis and enhances autophagy in lipopolysaccharide-stimulated RAW 264.7 macrophages.
He J; Wang Y; Xu LH; Qiao J; Ouyang DY; He XH
Int Immunopharmacol; 2013 May; 16(1):27-34. PubMed ID: 23541744
[TBL] [Abstract][Full Text] [Related]
13. Cucurbitacin IIb from Ibervillea sonorae Induces Apoptosis and Cell Cycle Arrest via STAT3 Inhibition.
Torres-Moreno H; Marcotullio MC; Velazquez C; Arenas-Luna VM; Hernández-Gutiérrez S; Robles-Zepeda RE
Anticancer Agents Med Chem; 2020; 20(10):1188-1196. PubMed ID: 32294048
[TBL] [Abstract][Full Text] [Related]
14. Cucurbitacin IIa interferes with EGFR-MAPK signaling pathway leads to proliferation inhibition in A549 cells.
Zhang J; Song Y; Liang Y; Zou H; Zuo P; Yan M; Jing S; Li T; Wang Y; Li D; Zhang T; Wei Z
Food Chem Toxicol; 2019 Oct; 132():110654. PubMed ID: 31265865
[TBL] [Abstract][Full Text] [Related]
15. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells.
Ku JM; Kim SR; Hong SH; Choi HS; Seo HS; Shin YC; Ko SG
Mol Cell Biochem; 2015 Nov; 409(1-2):33-43. PubMed ID: 26169986
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effects of natural and semisynthetic cucurbitacins on lung cancer cell line A549.
Silva IT; Geller FC; Persich L; Dudek SE; Lang KL; Caro MS; Durán FJ; Schenkel EP; Ludwig S; Simões CM
Invest New Drugs; 2016 Apr; 34(2):139-48. PubMed ID: 26780083
[TBL] [Abstract][Full Text] [Related]
17. Cucurbitacin I elicits the formation of actin/phospho-myosin II co-aggregates by stimulation of the RhoA/ROCK pathway and inhibition of LIM-kinase.
Sari-Hassoun M; Clement MJ; Hamdi I; Bollot G; Bauvais C; Joshi V; Toma F; Burgo A; Cailleret M; Rosales-Hernández MC; Macias Pérez ME; Chabane-Sari D; Curmi PA
Biochem Pharmacol; 2016 Feb; 102():45-63. PubMed ID: 26707799
[TBL] [Abstract][Full Text] [Related]
18. Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin.
Liu T; Peng H; Zhang M; Deng Y; Wu Z
Eur J Pharmacol; 2010 Sep; 641(1):15-22. PubMed ID: 20483353
[TBL] [Abstract][Full Text] [Related]
19. Cucurbitacin: ancient compound shedding new light on cancer treatment.
Lee DH; Iwanski GB; Thoennissen NH
ScientificWorldJournal; 2010 Mar; 10():413-8. PubMed ID: 20209387
[TBL] [Abstract][Full Text] [Related]
20. ANTITUMOR AND APOPTOTIC EFFECTS OF CUCURBITACIN A IN A-549 LUNG CARCINOMA CELLS IS MEDIATED VIA G2/M CELL CYCLE ARREST AND M-TOR/PI3K/AKT SIGNALLING PATHWAY.
Wang WD; Liu Y; Su Y; Xiong XZ; Shang D; Xu JJ; Liu HJ
Afr J Tradit Complement Altern Med; 2017; 14(2):75-82. PubMed ID: 28573224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
